Evidence map›Paper›PMID 34900545›Full record

ArticleActa pharmaceutica Sinica. B2021

Spatial-resolved metabolomics reveals tissue-specific metabolic reprogramming in diabetic nephropathy by using mass spectrometry imaging.

Zhonghua Wang, Wenqing Fu, Meiling Huo, Bingshu He, Yaqi Liu, Lu Tian, Wanfang Li, Zhi Zhou, Baili Wang, Jianzhen Xia and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review of methods for the determination of cellular cholesterol content: principles, advantages, limitations, applications, and perspectives.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Zhonghua WangKey Laboratory of Mass Spectrometry Imaging and Metabolomics (Minzu University of China), National Ethnic Affairs Commission, Beijing 100081, China.
Wenqing FuKey Laboratory of Mass Spectrometry Imaging and Metabolomics (Minzu University of China), National Ethnic Affairs Commission, Beijing 100081, China.
Meiling HuoKey Laboratory of Mass Spectrometry Imaging and Metabolomics (Minzu University of China), National Ethnic Affairs Commission, Beijing 100081, China.
Bingshu HeCollege of Life and Environmental Sciences, Minzu University of China, Beijing 100081, China.
Yaqi LiuCollege of Life and Environmental Sciences, Minzu University of China, Beijing 100081, China.
Lu TianNew Drug Safety Evaluation Center, Institute of Materia Medica, Peking Union Medical College, Beijing 100050, China.
Wanfang LiNew Drug Safety Evaluation Center, Institute of Materia Medica, Peking Union Medical College, Beijing 100050, China.
Zhi ZhouKey Laboratory of Mass Spectrometry Imaging and Metabolomics (Minzu University of China), National Ethnic Affairs Commission, Beijing 100081, China.
Baili WangSchool Hospital, Minzu University of China, Beijing 100081, China.
Jianzhen XiaSchool Hospital, Minzu University of China, Beijing 100081, China.
Yanhua ChenKey Laboratory of Mass Spectrometry Imaging and Metabolomics (Minzu University of China), National Ethnic Affairs Commission, Beijing 100081, China.
Jinfeng WeiNew Drug Safety Evaluation Center, Institute of Materia Medica, Peking Union Medical College, Beijing 100050, China.
Zeper AblizKey Laboratory of Mass Spectrometry Imaging and Metabolomics (Minzu University of China), National Ethnic Affairs Commission, Beijing 100081, China.
Minzu University of China · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Detailed knowledge on tissue-specific metabolic reprogramming in diabetic nephropathy (DN) is vital for more accurate understanding the molecular pathological signature and developing novel therapeutic strategies. In the present study, a spatial-resolved metabolomics approach based on air flow-assisted desorption electrospray ionization (AFADESI) and matrix-assisted laser desorption ionization (MALDI) integrated mass spectrometry imaging (MSI) was proposed to investigate tissue-specific metabolic alterations in the kidneys of high-fat diet-fed and streptozotocin (STZ)-treated DN rats and the therapeutic effect of astragaloside IV, a potential anti-diabetic drug, against DN. As a result, a wide range of functional metabolites including sugars, amino acids, nucleotides and their derivatives, fatty acids, phospholipids, sphingolipids, glycerides, carnitine and its derivatives, vitamins, peptides, and metal ions associated with DN were identified and their unique distribution patterns in the rat kidney were visualized with high chemical specificity and high spatial resolution. These region-specific metabolic disturbances were ameliorated by repeated oral administration of astragaloside IV (100 mg/kg) for 12 weeks. This study provided more comprehensive and detailed information about the tissue-specific metabolic reprogramming and molecular pathological signature in the kidney of diabetic rats. These findings highlighted the promising potential of AFADESI and MALDI integrated MSI based metabolomics approach for application in metabolic kidney diseases.

Indexed as

ADP, adenosine diphosphateAFADESI, air flow-assisted desorption electrospray ionizationAGEs, advanced glycation end productsAMP, adenosine monophosphateAMPK, adenosine monophosphate activated protein kinaseAST, astragaloside IVAstragaloside IVATP, adenosine triphosphateBUN, blood urea nitrogenCL, cardiolipinCre, creatinineDAG, diacylglycerolDESI, desorption electrospray ionizationDiabetic nephropathyDM, diabetes mellitusDN, diabetic nephropathyDPA, docosapentaenoic acidESKD, end-stage kidney diseaseFBG, fasting blood glucoseGLU, glucoseGMP, guanosine monophosphateGSH, glutathioneHbA1c, glycosylated hemoglobinH&E, hematoxylin and eosinHPLC, high-performance liquid chromatographyLysoPC, lysophosphatidylcholineLysoPG, lysophosphatidylglycerolMALDI, matrix-assisted laser desorption ionizationMass spectrometry imagingMetabolic reprogrammingMSI, mass spectrometry imagingMS, mass spectrometryNa-CMC, sodium carboxymethyl celluloseNMR, nuclear magnetic resonancep-AMPK, phosphorylated adenosine monophosphate activated protein kinasePA, phosphatidic acidPC, phosphatidylcholinePE, phosphatidylethanolaminePG, phosphatidylglycerolPPP, pentose phosphate pathwayPS, phosphatidylserinePUFA, polyunsaturated fatty acidsROI, regions of interestROS, reactive oxygen speciesSDH, succinate dehydrogenaseSGLTs, sodium-glucose cotransportersSM, sphingomyelinSpatial-resolved metabolomicsSTZ, streptozotocinTCA, tricarboxylic acidTCHO, total cholesterolTG, triglycerideUMP, uridine monophosphateVIP, variable importance in projection

Identifiers

PMID34900545
PMCPMC8642449
OpenAlexW3164968925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.